Himalayas-1
36 evidence topics · 13 sources
Objective
Primary objective: radiographic progression-free survival superiority
Location and study date
Registry status and dates
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |
| First posted | “2026-07-23” |
Anticipated primary endpoint readout relative to cash runway
Study design
Randomized phase 3 design with physician's choice of control
| Study characteristic | Quoted record |
|---|---|
| Design | “Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Protocol number | “ORIC-944-05” |
| EU trial number | “2026-525340-15-00” |
Randomization and stratification
Protocol finalized after end-of-phase 1 interactions with regulators
Sponsorship and darolutamide supply agreement
Eligibility criteria
Excluded and permitted prior therapies in the registry record
Treatment
Investigational and control regimens
| Study drug and arm | Quoted dose and schedule |
|---|---|
| Rinzimetostat (investigational arm) | “400 mg once daily (QD)” |
| Darolutamide (investigational arm and physician's choice) | “600 mg twice daily (BID)” |
| Enzalutamide (physician's choice) | “160 mg once daily (QD)” |
| Docetaxel (physician's choice) | “75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles” |
Basis for the rinzimetostat dose
Study outcomes
Rationale for using radiographic progression-free survival by blinded independent central review as the primary endpoint
Trial definition of radiographic progression-free survival
Key secondary endpoint: overall survival
Other secondary efficacy, safety, and pharmacokinetic endpoints
Patient-reported outcome endpoints
Consensus definition of radiographic progression-free survival
“Radiographic progression-free survival (rPFS) is the time interval from random assignment to the date when the first site of disease is found to progress (using a manifestation-specific definition of progression), or death, whichever occurs first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of particular note is the use of the 2+2 rule to distinguish flare from true progression in patients with osseous disease at baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus position on the association with overall survival
“The association between rPFS and overall survival is still being investigated, but an association was demonstrated in at least one of these trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The suitability of efficacy end points to demonstrate clinical benefit is context dependent, and consultation with regulatory authorities is strongly recommended when selecting and defining end points for a trial intended to support drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with abiraterone
“Spearman's correlation coefficient between rPFS and OS was 0.72.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data make no surrogate claims of rPFS and do not provide support for the use of rPFS to serve as a substitute for OS at this juncture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with enzalutamide
“Spearman ρ was 0.72 (95% CI, 0.67-0.76) among all patients, 0.89 (95% CI, 0.86-0.92) among enzalutamide-treated patients, and 0.53 (95% CI, 0.43-0.61) among placebo-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our analysis, the lower correlation between rPFS and OS seen with placebo-treated patients than seen with enzalutamide-treated patients could be partly related to postprotocol exposure to life-prolonging therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-level correlation with overall survival after prior androgen receptor pathway inhibitor and taxane
“In the overall population, rPFS correlated strongly with OS (rho ≥ 0.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Correlations between rPFS or OS and time to SSE without death were weak or mild.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial-level surrogacy in first-line mCRPC naive to androgen receptor pathway inhibitors
“Eleven RCTs were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using the methodology recommended by the German health authority IQWiG, this study supports rPFS as a valid intermediate endpoint for OS in first-line ARPi naïve mCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial-level surrogacy across advanced prostate cancer
“A total of 143 randomized trials (n=75,601 patients) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“radiographic PFS [n=52,548], 0.50 [95% CI, 0.35 to 0.63]” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical progression without radiographic progression
“Of 736 patients with disease progression, 280 (38%) had UCP-only and 124 (17%) had UCP plus RAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Including UCP events lowered estimates of treatment benefit—median crPFS was 13.3 months (95% CI 11.1 to 13.8) versus median rPFS of 16.5 months (95% CI 13.8 to 16.8) in AAP group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment by sites and countries
Description of analysis sets
Planned primary analysis of radiographic progression-free survival
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: design and data limitations
- No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
- The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
- The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
- Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
- Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
- The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.